Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Yukio Yonetani.
Journal of Cardiovascular Pharmacology | 1996
Masaru Kawakami; Shoichi Matsumura; Toshitake Shimamura; Takanori Iwasaki; Hitoshi Furukawa; Kazuki Matsunaga; Yukio Yonetani; Kazumi Iwaki
S-2150 is a new 1,5-benzothiazepine derivative possessing both calcium channel-blocking and alpha 1-adrenoceptor-blocking effects. In isolated rat thoracic aorta precontracted with KCl (18 mM), the 50% inhibitory concentration (IC50) value was 190 nM for S-2150, which was similar to that of diltiazem. In aorta precontracted with phenylephrine (0.3 microM), IC50 values of S-2150 and diltiazem were 29 nM and > 10 microM, respectively. The relative contribution of calcium channel-blocking and alpha 1-adrenoceptor-blocking activities to hypotension was determined by using anesthetized rats before and after masking of the alpha 1-receptors with prazosin. The hypotensive effect of S-2150 [0.3 and 1 mg/kg intravenously (i.v.)] was attenuated by 40% after prazosin treatment, whereas that of diltiazem was not. In conscious spontaneously hypertensive rats (SHRs), renal hypertensive rats, and normotensive rats, S-2150 [10, 30, and 60 mg/kg orally (p.o.)] caused dose-dependent hypotensive effects. The effect of S-2150 was 4-7 times more potent than that of diltiazem. There were no changes in the hypotensive effects with consecutive administration of S-2150 during 6-8 weeks in SHRs and stroke-prone SHRs (SHRSPs). In SHRSPs, S-2150 reduced the mortality by stroke and small arterial hyperplasia in abdominal organs and also ameliorated renal excretory function. These results suggest that S-2150 may be a useful antihypertensive agent possessing both calcium-antagonistic and alpha 1-adrenoceptor-blocking effects.
Pediatric Research | 1988
Toshihiro Shinosaki; Yukio Yonetani
A stop-flow technique using pyrazinoic acid(PZO)-treated and -untreated rats was devised to evaluate drug effects on bi-directional transport of uric acid in the tubules. Constant venous infusion of test drugs to PZO-untreated rats was used to estimate their inhibitory effects on urate secretion, while their inhibitory effects on urate reabsorption was studied by intravenous administration as a bolus to PZO-treated rats. Probenecid, tienilic acid and R-(+)-enantiomer of S-8666, which is the uricosuric component of a new uricosuric diuretic, decreased the (Tua/Pua)/(Tin/Pin) value in the distal and proximal tubules by inhibiting urate secretion in PZO-untreated rats. On the other hand, all of these drugs increased the (Tua/Pua)/(Tin/Pin) value in the tubules in PZO-treated rats, which suggested that they also inhibited the reabsorptive flux of urate. This stop-flow technique in rat kidneys showed the possibilities of bi-directional inhibition by these drugs of urate transport in the tubules.
Journal of Hypertension | 1999
Toshitake Shimamura; Masatoshi Nakajima; Takanori Iwasaki; Yoko Hayasaki; Yukio Yonetani; Kazumi Iwaki
Archive | 1976
Yasunao Ogawa; Yukio Yonetani
Japanese Journal of Pharmacology | 1987
Yukio Yonetani; Kazumi Iwaki; Toshihiro Shinosaki; Atsuko Kawase-Hanafusa; Hiroshi Harada; Arthur A. van Es
Japanese Journal of Pharmacology | 1983
Yukio Yonetani; Kazumi Iwaki
Archive | 1990
Hiroshi Harada; Eiichi Ohsugi; Yukio Yonetani; Toshihiro Shinosaki
Japanese Journal of Pharmacology | 1984
Kazumi Iwaki; Yukio Yonetani
Japanese Journal of Pharmacology | 1980
Yukio Yonetani; Mitsuo Ishii; Kazumi Iwaki
Archive | 1974
Kaoru Ishitobi; Hideyuki Maekawa; Yasunao Ogawa; Yukio Yonetani